Mathematical and pharmacokinetic approaches for the design of new 3D printing inks using ricobendazole

Dublin Core

Título

Mathematical and pharmacokinetic approaches for the design of new 3D printing inks using ricobendazole

Tema

IMPRESION 3D
FARMACOCINETICA
FARMACOMETRIA
MODELADO MATEMATICO
SULFOXIDO DE ALBENDAZOL
BIBLIOGRAFIA NACIONAL QUIMICA
2022

Abstract

Purpose 3D printing (3DP) makes it possible to obtain systems that are not achievable with current conventional methods, one of them, sustained release floating systems. Floating systems using ricobendazole (RBZ) as a model drug and a combination of polymers were designed and obtained by melt solidification printing technique (MESO-PP). Methods Four different MESO-PP inks were formulated based on combinations of the polymers Gelucire 43/01 and Gelucire 50/13 in different ratios. For each of the formulated inks, physicochemical characterization was performed by thermal analysis (thermogravimetric analysis [TGA] and differential scanning calorimetry [DSC]), fourier transform infrared spectrophotometer (FTIR) and X-ray diffraction (XRD). Pharmaceutical characterization was performed by in vitro assays to determine pharmaceutically relevant parameters. These parameters were calculated by applying mathematical models developed to evaluate in vitro drug release profiles. On the other hand, a physiologically based pharmacokinetic (PBPK) model was developed to predict the in vivo performance of RBZ loaded in the different inks by determining the Cmax, and the AUC 0-∞. Results By increasing the proportion of Gelucire 50/13 co-surfactant in the mixtures (the proportion in Ink 1 was 33%, while the proportion in Ink 4 was 80%), the dissolution capacity of RBZ increases substantially, decreasing flotation times. Conclusion MESO-PP produced ink 1 (50% Gelucire 43/01, 25% Gelucire 50/13 and 25% RBZ), which has a zero-order release (RR = 0.180%/min) and the longest flotation time (545 ± 23 min), and in turn would produce a significant increase in oral absorption of the drug, with an AUC 0-∞ 2.16-fold higher than that obtained in animals treated with RBZ loaded in conventional tablets.

Autor

Barberis, María Eugenia
Palma, Santiago Daniel
Gonzo, Elio Emilio
Bermúdez, José María
Real, Juan Pablo

Fuente

Pharmaceutical Research, 2022

Editor

Springer

Fecha

2022

Derechos

Información sobre Derechos de Autor

(Por favor lea este aviso antes de abrir los documentos u objetos)

La legislación uruguaya protege el derecho de autor sobre toda creación literaria, científica o artística, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeción a lo establecido por el derecho común y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)

ADVERTENCIA: La consulta de este documento queda condicionada a la aceptación de las siguientes condiciones de uso: Este documento es únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilización o cita de partes debe indicarse el nombre de la persona autora.

Formato

PDF

Extent

14 p.

Idioma

Inglés

Tipo

Artículo

Identificador

10.1007/s11095-022-03320-z

Document Item Type Metadata

Original Format

PDF
Fecha de agregación
August 26, 2022
Colección
Bibliografía Nacional Química
Tipo de Elemento
Document
Citación
Barberis, María Eugenia, “Mathematical and pharmacokinetic approaches for the design of new 3D printing inks using ricobendazole,” RIQUIM - Repositorio Institucional de la Facultad de Química - UdelaR, accessed December 5, 2022, http://riquim.fq.edu.uy/items/show/6543.
Archivos